SUMMARY The cerebrospinal fluid (CSF) concentrations of arginine vasopressin (AVP) and oxytocin (OT) were investigated both in patients with benign intracranial hypertension and in age and sex matched controls. Twenty eight lumbar punctures were performed on 15 patients with benign intracranial hypertension as part of their routine investigation and therapy. All patients had raised intracranial pressure (27.4, SE 1-7 cm.CSF). CSF AVP levels were significantly elevated in benign intracranial hypertension (2' 1, SE 0 3 pmol/l) compared with controls (0 7, SE 0O 1 pmol/l, p < 0-001) but CSF OT concentrations were similar in both groups. CSF osmolality and plasma AVP and osmolality were identical in patients and controls. There was no correlation between CSF AVP concentration and intracranial pressure. The selective elevation of AVP in CSF may be of importance in the pathogenesis of raised intracranial pressure in benign intracranial hypertension.
Arginine vasopressin (AVP) and oxytocin (OT) are widely distributed in the CNS, not only in the hypothalamus, but also in various extrahypothalamic regions and the spinal cord.'`3 Both peptides have also been demonstrated in CSF by bioassay and radioimmunoassay techniques.4" The blood-brain barrier prevents access of circulating AVP and OT to the CSF. 5 In addition, the classical physiological stimuli to neurohypophysial peptide secretion do not result in marked alterations of CSF concentrations of OT or AVP, suggesting that the CSF peptides have distinct origins and regulation from the hypothalamoneurohypophysial system. The functions of these hormones in the brain and CSF are unknown.
There is accumulating evidence for an association between elevated CSF AVP concentrations and disorders associated with raised intracranial pressure (ICP) including benign intracranial hypertension, 9 subarachnoid haemorrhage'°and meningitis." It is not known whether the rise in CSF AVP is part of the primary pathology or simply a non-specific response to changes in ICP.
We have recently demonstrated'2 that intracerebroventricular infusion of AVP in the cons-cious goat leads to elevation of ICP by a mechanism independent of any effect on systemic arterial blood pressure or circulating AVP. We have therefore investigated CSF neurohypophysial peptide concentrations in patients with benign intracranial hypertension and controls.
Methods
Fifteen patients with benign intracranial hypertension (mean age 35 5y, range 14-55y; 13F:2M) were investigated (table 1). All gave their informed consent to the study which had been approved by the local ethical committee. All had papilloedema and enlarged blind spots. Ventricular size was normal or symmetrically decreased on computed tomography (CT); two also showed empty sellae, a feature associated with elevated intracranial pressure (table 1) . Ten patients were on no medication prior to study, one was receiving paracetamol for headaches, one was taking diuretics and three were taking acetazolamide. One patient on acetazolamide was receiving chronic lithium carbonate therapy for manic depressive disease. CSF was obtained at routine lumbar puncture (LP), which was performed between 09:00 and 12:00h, under local anaesthesia. Some patients were investigated more than once (total of 28 LPs). Patients were positioned recumbent for 30 min prior to LP. A blood sample was taken and then LP was performed in the lateral decubitus position. Intracranial pressure was estimated by direct manometry before samples were obtained for routine biochemistry, microscopy and peptide and osmolality estimation. Serial 5 ml aliquots of CSF were obtained from 13 patients.
The controls (mean age 35 5y, range 18-61y; l0F:6M) comprised 16 patients undergoing LP as part of the routine investigation of lumbar disc disease (8), headache (3), possible multiple sclerosis (3), acute myeloid leukaemia without CNS involvement (1) and benign cerebral calcification (1). Paired blood and CF samples were obtained after 30 min recumbency and treated similarly to samples from benign intracranial hypertension patients.
Analyses
Venous blood was collected into lithium heparin tubes on ice, centrifuged at 4°C, the plasma separated, an aliquot retained for osmolality estimation by freezing point depression, and the remainder stored at -20°C for subsequent peptide radioimmunoassay. CSF was stored at -20°C. Plasma was extracted through octadecasilyl silica cartridges (Sep-pak C18, Waters Associates, Milford, MA) prior to peptide estimation by sensitive and specific radioimmunoassays.'3 Extraction yield was >90% for both OT and AVP; no correction for yield was made. CSF peptides were estimated directly. Intraassay coefficient of variation was < 5% for both OT and AVP ((2 fmol standard, 10 replicates). Interassay coefficients of variation were 10% for OT 
Results
Intracranial pressure was significantly (p < 0-001) elevated in patients with benign intracranial hypertension (27-4, SE 1-5 cm.CSF) compared with controls (13-6, SE 1-7 cm.CSF). CSF protein concentration (0 47, SE 0 04 g/l in benign intracranial hypertension, 0-48, SE 0-07 g/l in controls) and CSF cell counts were similar in both groups.
CSF AVP concentration was 2 1, SE 0 3 pmol/l in benign intracranial hypertension patients, significantly greater than controls (0-7, SE 0-1 pmol/l, p < 0-001). CSF OT levels however, were similar in patients (9 3, SE 11 pmol/l) and controls (8-8, SE 1-4 pmol/l). Examination of the data (fig) revealed a single control CSF OT value considerably higher than the rest. Exclusion of this point reduced mean (but not median) control CSF OT to 7-8 SE 0-9 pmol/l, but this adjusted control value was also not significantly lower than CSF OT in benign intracranial hypertension patients (p = 0 49).
Plasma AVP and osmolality and CSF osmolality were identical in both patients and controls, (table 2) . There were no significant differences between the CSF AVP concentrations in the first (2 1, SE 0-2 pmol/l) and the last (1-7, SE 0-2 pmol/l) aliquots of CSF, nor were there differences between the initial (8-9, SE 1 7 pmol/l) and final (8-9, SE 1-3 pmol/l) CSF OT levels. There was no correlation between CSF AVP and intracranial pressure in either patients (r = -0 2), controls, or combined patients and controls (r = 0 1). HPLC analysis of CSF from patients with benign On the other hand, CSF OT was identical in patients and controls, suggesting that the elevation of CSF AVP in benign intracranial hypertension does not represent a non-specific release of peptides secondary to the pathological process. OT is a particularly good control for AVP in view of its similar structure and distribution throughout the CNS.314 The elevation of AVP, but not OT, in CSF is unlikely to reflect differences in the clearance rates of these similar nonapeptides.5 In addition, the HPLC analysis provides strong evidence that the immunoreactivity measured is authentic AVP rather than any accumulating metabolic product or cross-reacting substance present in the CSF in benign intracranial hypertension. Furthermore, the overlap of values between benign intracranial hypertension and con- 
